OTCPK:RFCS

Stock Analysis Report

Executive Summary

Refocus Group, Inc., a medical device company, engages in the research and development of treatments for human vision disorders, primarily for presbyopia.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Refocus Group's last earnings update was 5055 days ago.
  • Refocus Group is not covered by any analysts.

Share Price & News

How has Refocus Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:RFCS

1.5%

US Medical Equipment

0.8%

US Market


1 Year Return

-67.0%

OTCPK:RFCS

9.7%

US Medical Equipment

1.9%

US Market

RFCS underperformed the Medical Equipment industry which returned 9.6% over the past year.

RFCS underperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

RFCSIndustryMarket
7 Day0%1.5%0.8%
30 Day-9.4%0.7%3.4%
90 Day-19.4%2.4%2.1%
1 Year-67.0%-67.0%10.6%9.7%4.2%1.9%
3 Year-9.4%-9.4%70.2%65.0%46.7%37.2%
5 Year141.7%141.7%136.0%109.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is Refocus Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Refocus Group undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Refocus Group is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Refocus Group has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Refocus Group's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Refocus Group regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Refocus Group expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Refocus Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Refocus Group performed over the past 5 years?

0.2%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Refocus Group has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Refocus Group's financial position?


In this section we usually analyse Refocus Group's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Refocus Group has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of RFCS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Refocus Group's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Refocus Group's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Refocus Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Refocus Group's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Refocus Group has not reported any payouts.

Unable to verify if Refocus Group's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Refocus Group has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Refocus Group's salary, the management and board of directors tenure and is there insider trading?

5.8yrs

Average management tenure


CEO

Mike Judy (58yo)

5.9yrs

Tenure

0

Mr. J. Michael Judy, also known as Mike, has been the Chief Executive Officer and President of Refocus Group Inc., since October 28, 2013. Mr. Judy served as the Chief Commercialization Officer of Acufocus ...


Management Age and Tenure

5.8yrs

Average Tenure

The average tenure for the Refocus Group management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

5.7yrs

Average Tenure

70yo

Average Age

The tenure for the Refocus Group board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Management Team

  • Zack Thompson

    CFO & Senior VP of Business Development

    • Tenure: 8.4yrs
  • Mike Judy (58yo)

    CEO, President & Director

    • Tenure: 5.9yrs
  • Marga Wastalu

    Director of Clinical Affairs

    • Tenure: 5.4yrs
  • David Schanzlin

    Chief Medical Officer

    • Tenure: 7.6yrs
  • Kevin Cady

    Vice President of Marketing & Business Development

    • Tenure: 4.7yrs
  • Martin Kaufman

    Chief Regulatory Officer

    • Tenure: 5.7yrs

Board Members

  • Thomas Loarie (72yo)

    Chairman of the Board

    • Tenure: 0.7yrs
  • Harry Jacobson (71yo)

    Director

    • Tenure: 8.7yrs
  • Tim Lyles (62yo)

    Director

    • Tenure: 14.7yrs
  • Don Phillips (70yo)

    Director

    • Tenure: 2.7yrs
  • Mike Judy (58yo)

    CEO, President & Director

    • Tenure: 5.9yrs

Company Information

Refocus Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Refocus Group, Inc.
  • Ticker: RFCS
  • Exchange: OTCPK
  • Founded: 1994
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$1.789m
  • Shares outstanding: 24.67m
  • Website: https://www.refocus-group.com

Location

  • Refocus Group, Inc.
  • 10210 North Central Expressway
  • Suite 400
  • Dallas
  • Texas
  • 75231
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RFCSOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMar 2003

Biography

Refocus Group, Inc., a medical device company, engages in the research and development of treatments for human vision disorders, primarily for presbyopia. The company develops VisAbility Micro-Insert Syste ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 23:52
End of Day Share Price2019/09/17 00:00
Earnings2005/09/30
Annual Earnings2004/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.